Angiogenesis, protein and gene delivery.
Advances in our understanding of angiogenesis and blood vessel growth have given rise to efforts to develop novel therapeutic approaches for patients with ischaemia who are not adequately treated with presently available therapies. Among the growth factors that play a role in blood vessel growth and development, vascular endothelial growth factors and fibroblast growth factors have been the most extensively studied. Various methods of delivery have been utilized to enhance localization and persistence, including methods for delivery of proteins as well as gene transfer techniques. Initial clinical trials have now been undertaken. Preliminary information on efficacy is beginning to become available, raising hopes, as well as questions about the future direction and potential success of therapeutic angiogenesis as a clinical approach to the treatment of ischaemia.
Azrin
M
M
Cardiology Division, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.
D000256:Adenoviridae / Q000235:genetics; D002986:Clinical Trials as Topic; D004247:DNA / Q000008:administration & dosage; D016228:Endothelial Growth Factors / Q000235:genetics; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006133:Growth Substances / Q000008:administration & dosage* / Q000235:genetics; D006801:Humans; D008222:Lymphokines / Q000235:genetics; D017202:Myocardial Ischemia / Q000628:therapy*; D018919:Neovascularization, Physiologic; D012190:Retroviridae / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D006133:Growth Substances; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D004247:DNA